Overseas cost Rs 3-4 crore
20-30 lakhs in the country
: Good news for leukemia and lymphoma sufferers. The state-of-the-art ‘Car-T Cell’ treatment for these two types of cancers will be available in our country from next year! He currently has to travel to the United States for treatment. Therefore, it is costing around Rs 3-4 crore. Apart from that, IIT-Bombay-based ‘Immunoactive’ is all set to make the treatment available in India for less than Rs 20-30 lakh.
The important thing is that the car-T cell therapy offered by this company is developed entirely domestically. Rahul Panwar, CEO and Founder, Immunoact, Senior Faculty, IIT Bombay, has been researching and developing this treatment for eight years. Launched at the Society of Innovation and Entrepreneurship at IIT Bombay, Immunoact is now a partnership with Hyderabad-based pharma giant Larus Labs. The health center, which opened on June 11, is expected to treat 1,200 patients a year. The first phase of the treatment, developed by Rahul Panwar, was conducted on 10 lymphoma patients at the Advanced Center for Treatment, Research and Education in Cancer at the Tata Memorial Hospital, Mumbai.
All of them are in good condition now. Medical experts say no one has been diagnosed with cancer. In this context, the Immunoactive Company is seeking permission from CDSCivo to conduct clinical trials on 40 patients in the second phase. It is estimated that between 40,000 and 50,000 cases of leukemia and lymphoma are reported in the country every year. In this context .. For those who cannot go abroad and undergo car-t cell treatment, it is hard to find that treatment here. Carotid cells are chemically antigen receptor (carotenoid) cells. These are immune cells. These cells are collected from the patient’s body and modified in a lab to fight cancer. This treatment works well for leukemia and lymphoma. Research is underway to provide this treatment for autoimmune diseases as well.
To whom is it given?
The last stage is for leukemia and lymphoma patients. It is also for those who do not respond to conventional therapies such as chemotherapy and herbal transplants. Research abroad has shown that better results are coming.
